|
Jul 1
|
Alvotech and Advanz Pharma Enter into European Supply and Commercialization Agreement for Biosimilar Candidate to Cimzia® (certolizumab pegol)
|
|
Jun 27
|
Exploring 3 High Growth Tech Stocks in the US Market
|
|
Jun 26
|
Alvotech, Kashiv, Advanz announce study of AVT23 met primary endpoint
|
|
Jun 26
|
Alvotech’s Lenders Lower Interest on Senior Secured Term Loan Facility
|
|
Jun 25
|
US High Growth Tech Stocks To Watch In June 2025
|
|
Jun 25
|
Positive Top Line Results from Confirmatory Efficacy Study for Proposed Biosimilar to Xolair® (omalizumab)
|
|
Jun 11
|
Alvotech’s Private Placement Completed with Delivery of SDRs and Shares to Investors
|
|
May 28
|
Alvotech and Advanz Pharma Extend Strategic Partnership to Commercialize Three Additional Biosimilars in Europe
|
|
Jan 27
|
Alvotech and Teva Announce Filing Acceptance of U.S. Biologics License Applications for AVT05, a Proposed Biosimilar to Simponi® and Simponi Aria® (golimumab)
|
|
Jan 26
|
Alvotech's (NASDAQ:ALVO) largest shareholders are private equity firms with 34% ownership, private companies own 31%
|